Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study-Reference-Cited by-同舟云学术

Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study

Published:2020-09 Issue:17 Volume:8 Page:1048-1048
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann Transl Med

Author:

Huang Chen,Wu Lili,Liu Ruixia,Li Weijing,Li Zheng,Li Jianqiang,Liu Lihong,Shan Baoen

Publisher

AME Publishing Company

Subject

General Medicine

Link

http://atm.amegroups.com/article/download/49940/pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review;Hematology, Transfusion and Cell Therapy;2024-07

2. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis;Expert Review of Anti-infective Therapy;2022-09-28

3. Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis;Frontiers in Pharmacology;2022-04-25

4. Development of a Radiotracer for PET Imaging of the SNAP Tag;ACS Omega;2022-02-23

5. Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review: Efficacy and Safety of Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL);2021-10-26